Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase

Introduction. Erwinase® (native Erwinia chrysanthemi L-Asparaginase (nErA)) is an approved second-line treatment for acute lymphoblastic leukaemia (ALL) in children and adolescents, who develop hypersensitivity or neutralising antibodies to E.coli derived L-Asparaginases (ASNases). However, nErA has...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Tapasvi, Gervais, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Preclinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763762/
https://www.ncbi.nlm.nih.gov/pubmed/34468906
http://dx.doi.org/10.1007/s10637-021-01173-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763762/
https://www.ncbi.nlm.nih.gov/pubmed/34468906
http://dx.doi.org/10.1007/s10637-021-01173-8

Ejemplares similares